# Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

> **NCT01095887** · PHASE1,PHASE2 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 6 (actual)

## Conditions studied

- Kidney Transplant

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT01095887
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-05
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2015-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01095887

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01095887, "Eculizumab to Prevent Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01095887. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*